Results 111 to 120 of about 353,583 (326)

Relationship between lipid metabolism, coagulation and other blood indices and etiology and staging of non-traumatic femoral head necrosis: a multivariate logistic regression-based analysis

Journal of Orthopaedic Surgery and Research
Background To analyze the relationship between lipid metabolism, coagulation function, and bone metabolism and the contributing factor and staging of non-traumatic femoral head necrosis, and to further investigate the factors influencing the blood ...
Ximing Yu, Shilu Dou, Liaodong Lu, Meng Wang, Zhongfeng Li, Dongwei Wang   +5 more
doaj   +1 more source

Evaluation of Antiphospholipid Antibodies and Activated Partial Thromboplastin Time in Women with Adverse Outcome of Pregnancy [PDF]

Iranian Journal of Medical Sciences, 2010
Adverse outcome of pregnancy is a potentially dangerouscomplication of conception and affects 15-20% of pregnancies.According to recent studies increased level of bloodantiphospholipids antibodies, if accompanied by predisposingfactors, can be an adverse
Sariyeh Golmahammad lou, Nader Pashapour, Mahnaz khalili, Farzaneh Broomand, Fatemeh Bahadori   +4 more
doaj  

Activated partial thromboplastin time and clinical outcome after thrombin inhibition in unstable coronary artery disease [PDF]

, 1999
Jonas Oldgren
openalex   +1 more source

Safety and Use of Eptacog Beta 225 µg/kg in Patients With Haemophilia A or B With Inhibitors

Haemophilia, EarlyView.
Introduction Eptacog beta is an activated recombinant human factor VII bypassing agent approved for treating bleeding episodes (BEs) in patients aged ≥12 years with haemophilia A or B with inhibitors. Two initial dose regimens (IDRs) of either 75 or 225 µg/kg, followed by 75 µg/kg, are approved.
Manuel Carcao, Cédric Hermans, Adam Giermasz, Craig Kessler, Wolfgang Miesbach, Doris Quon, Jerzy Windyga, Johnny Mahlangu   +7 more
wiley   +1 more source

Estimating the Factor VIII‐Equivalent Activity of Emicizumab Using Global Assays of Haemostasis

Haemophilia, EarlyView.
ABSTRACT Background Emicizumab is a bispecific monoclonal antibody mimicking factor (F) VIII activity and an effective therapy for prophylaxis in people with haemophilia A (PWHA). The FVIII‐equivalent activity (FVIIIeq) of emicizumab remains unknown. Objectives To estimate FVIIIeq of emicizumab using global assays of haemostasis.
Daniel Kraemmer, Cihan Ay, Judit Rejtő, Georg Heinze, Peter Quehenberger, Ingrid Pabinger, Oliver Königsbrügge   +6 more
wiley   +1 more source

Effectiveness and safety of antithrombin for treatment of portal vein thrombosis: Nationwide prospective surveillance of 4 years of clinical experience in Japan

Hepatology Research, EarlyView.
Abstract Aim Antithrombin (AT), a plasma protein with anticoagulant properties, has a long‐standing medical history, primarily for treatment of congenital AT deficiency. Accumulated clinical experiences suggest AT is a potential anticoagulant for thrombotic diseases. This study aimed to clarify the effectiveness, safety, and clinical significance of AT
Shoichi Matsutani, Makoto Arakawa, Susumu Nakano   +2 more
wiley   +1 more source

Risk Factors for Traumatic Lumbar Puncture in Children With ALL

Acta Paediatrica, EarlyView.
Sirkku Setänen, Arja Harila, Viola Metsistö, Christoffer Ehrstedt   +3 more
wiley   +1 more source

Measuring Direct Oral Anticoagulant (DOAC) Levels: Applications, Limitations, and Future Directions

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction There are important challenges with the measurement and interpretation of direct oral anticoagulant (DOAC) anticoagulant effect including a lack of therapeutic ranges, inaccuracy of routinely available coagulation assays, lack of established thresholds for clinically significant effect, and uncertainty about how to apply the ...
Siraj Mithoowani, Chee Wee Tan, Deborah M. Siegal   +2 more
wiley   +1 more source

Classification of Platelet‐Activating Anti‐Platelet Factor 4 Disorders

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction The prototypic anti‐platelet factor 4 (PF4) disorder—heparin‐induced thrombocytopenia and thrombosis (HITT)—features immunoglobulin G (IgG) class antibodies that activate platelets, monocytes, and neutrophils in a mainly heparin‐dependent fashion via Fcγ receptor‐dependent cellular activation.
Theodore E. Warkentin
wiley   +1 more source

Variability of Argatroban Effects on the Multiple APTT Reagents in High and Low Coagulation Activity Samples

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction Argatroban is routinely monitored using activated partial thromboplastin time (APTT), with a recommended target range of 1.5–3.0 times. Although this range was established based on clinical trial data, including several APTT reagents, the differences in reactivity among APTT reagents remain unclear.
Osamu Kumano, Masahiro Ieko, Teruto Hashiguchi, Takashi Ito, Satoshi Yamazaki, Sumiyoshi Naito, Masako Yamazaki   +6 more
wiley   +1 more source